利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.04 秒)

    8-Oxoadenine Compound
    2.
    发明申请
    8-Oxoadenine Compound 审中-公开
    8-氧基腺嘌呤化合物

    公开(公告)号：US20070225303A1

    公开(公告)日：2007-09-27

    申请号：US10594074

    申请日：2005-03-25

    申请人： Haruhisa Ogita ,  Tomoaki Nakamura ,  Yoshiaki Isobe ,  Kazuki Hashimoto ,  Ayumu Kurimoto

    发明人： Haruhisa Ogita ,  Tomoaki Nakamura ,  Yoshiaki Isobe ,  Kazuki Hashimoto ,  Ayumu Kurimoto

    IPC分类号： A61K31/522 ,  C07D473/34

    CPC分类号： C07D473/16 ,  A61K31/522 ,  A61K31/5377 ,  C07D473/18 ,  C07D473/24 ,  C07D473/34

    摘要： An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1/Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral diseases and cancers, which is represented by the following formula (1): wherein A is a group of a formula represented by the formula (2): wherein R2 is a substituted or unsubstituted alkyl group and so on, R3 is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0˜2, X1 is oxygen atom, Z is straight or branched chain alkylene, and R1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.

    摘要翻译： 可用作对Th1 / Th2具有比活性的免疫调节剂的8-氧基腺嘌呤化合物，特别是用于过敏性疾病，病毒性疾病和癌症的局部应用的预防和治疗剂，其由下式（1）表示：其中 A是由式（2）表示的式的基团：其中R 2是取代或未取代的烷基等，R 3是氢原子或 烷基，R为卤素原子等，n为0〜2，X 1为氧原子，Z为直链或支链亚烷基，R 1为 任选被羟基，烷氧基，烷氧基羰基等取代的烷基或其药学上可接受的盐。

    Adenine compound and use thereof
    3.
    发明授权
    Adenine compound and use thereof 失效
    腺嘌呤化合物及其用途

    公开(公告)号：US07754728B2

    公开(公告)日：2010-07-13

    申请号：US10528343

    申请日：2003-09-26

    申请人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    发明人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    IPC分类号： C07D473/18 ,  C07D473/16 ,  A61K31/522 ,  A61P11/06 ,  A61P37/08

    CPC分类号： A61K31/5377 ,  A61K31/522 ,  A61K31/55

    摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

    摘要翻译： 用作局部给药的药物，其作为抗过敏剂有效。 用于局部给药的药物含有作为活性成分的由通式（1）表示的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳族烃或5至10元，单或双环， 含有1至3个选自0至2个氮原子，0或1个氧原子和0或1个硫原子的杂原子的芳族杂环; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

    NOVEL ADENINE COMPOUND AND USE THEREOF
    4.
    发明申请
    NOVEL ADENINE COMPOUND AND USE THEREOF 审中-公开
    新颖的化合物及其用途

    公开(公告)号：US20120178743A1

    公开(公告)日：2012-07-12

    申请号：US13402850

    申请日：2012-02-22

    申请人： Yoshiaki ISOBE ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    发明人： Yoshiaki ISOBE ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    IPC分类号： A61K31/52 ,  A61K31/5377 ,  A61P37/08 ,  A61P37/00 ,  A61P31/12 ,  A61P17/00 ,  C07D473/18 ,  A61K31/55

    CPC分类号： A61K31/5377 ,  A61K31/522 ,  A61K31/55

    摘要： An antiallergic agent for topical administration containing an adenine compound of general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

    摘要翻译： 一种用于局部给药的抗过敏剂，其含有通式（1）的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳烃或5至10元单或双环芳族杂环， 选自0至2个氮原子，0或1个氧原子和0或1个硫原子的3个杂原子; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

    Adenine derivatives
    5.
    发明授权
    Adenine derivatives 失效
    腺嘌呤衍生物

    公开(公告)号：US07157465B2

    公开(公告)日：2007-01-02

    申请号：US10474199

    申请日：2002-04-15

    申请人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Tetsuhiro Ogino ,  Ayumu Kurimoto ,  Hajime Kawakami

    发明人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Tetsuhiro Ogino ,  Ayumu Kurimoto ,  Hajime Kawakami

    IPC分类号： C07D473/16 ,  C07D473/18 ,  C07D473/24 ,  A61K31/52 ,  A61K31/522

    CPC分类号： C07D473/00 ,  C07D473/16 ,  C07D473/18 ,  C07D473/24 ,  C07D473/34

    摘要： This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.

    摘要翻译： 本发明涉及由通式（I）表示的腺嘌呤衍生物，其互变异构体或其药学上可接受的盐：其中X表示NR 3（其中R 3表示 氢原子或C 1-3烷基）等; R 1表示取代或未取代的烷基等; R 2表示羟基等; Y表示取代或未取代的芳族杂环等。 此外，本发明涉及包含上述衍生物作为活性成分的药物，例如干扰素诱导剂，抗病毒剂，抗癌剂，2型辅助T细胞选择性免疫应答抑制剂，抗过敏剂和免疫应答调节剂。

    NOVEL ADENINE COMPOUND AND USE THEREOF
    6.
    发明申请
    NOVEL ADENINE COMPOUND AND USE THEREOF 失效
    新颖的化合物及其用途

    公开(公告)号：US20100256118A1

    公开(公告)日：2010-10-07

    申请号：US12793649

    申请日：2010-06-03

    申请人： Yoshiaki ISOBE ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    发明人： Yoshiaki ISOBE ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    IPC分类号： A61K31/52 ,  C07D473/18 ,  A61K31/5377 ,  C07D473/24 ,  C07D473/16 ,  A61K31/55 ,  A61P11/06 ,  A61P17/00 ,  A61P37/02

    CPC分类号： A61K31/5377 ,  A61K31/522 ,  A61K31/55

    摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

    摘要翻译： 用作局部给药的药物，其作为抗过敏剂有效。 用于局部给药的药物含有作为活性成分的由通式（1）表示的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳族烃或5至10元，单或双环， 含有1至3个选自0至2个氮原子，0或1个氧原子和0或1个硫原子的杂原子的芳族杂环; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

    Adenine compound and use thereof
    8.
    发明授权
    Adenine compound and use thereof 失效
    腺嘌呤化合物及其用途

    公开(公告)号：US08148371B2

    公开(公告)日：2012-04-03

    申请号：US12793649

    申请日：2010-06-03

    申请人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    发明人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P37/08 ,  A61P11/06 ,  C07D473/40 ,  C07D473/16

    CPC分类号： A61K31/5377 ,  A61K31/522 ,  A61K31/55

    摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

    摘要翻译： 用作局部给药的药物，其作为抗过敏剂有效。 用于局部给药的药物含有作为活性成分的由通式（1）表示的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳族烃或5至10元，单或双环， 含有1至3个选自0至2个氮原子，0或1个氧原子和0或1个硫原子的杂原子的芳族杂环; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

    Novel adenine derivatives
    9.
    发明申请
    Novel adenine derivatives 失效
    新型腺嘌呤衍生物

    公开(公告)号：US20070037832A1

    公开(公告)日：2007-02-15

    申请号：US11582452

    申请日：2006-10-18

    申请人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Tetsuhiro Ogino ,  Ayumu Kurimoto ,  Hajime Kawakami

    发明人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Tetsuhiro Ogino ,  Ayumu Kurimoto ,  Hajime Kawakami

    IPC分类号： A61K31/52

    CPC分类号： C07D473/00 ,  C07D473/16 ,  C07D473/18 ,  C07D473/24 ,  C07D473/34

    摘要： This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.

    摘要翻译： 本发明涉及由通式（I）表示的腺嘌呤衍生物，其互变异构体或其药学上可接受的盐：其中X表示NR 3（其中R 3表示 氢原子或C 1-3烷基）等; R 1表示取代或未取代的烷基等; R 2表示羟基等; Y表示取代或未取代的芳族杂环等。 此外，本发明涉及包含上述衍生物作为活性成分的药物，例如干扰素诱导剂，抗病毒剂，抗癌剂，2型辅助T细胞选择性免疫应答抑制剂，抗过敏剂和免疫应答调节剂。

    Novel adenine compound and use thereof
    10.
    发明申请
    Novel adenine compound and use thereof 失效
    新型腺嘌呤化合物及其用途

    公开(公告)号：US20060052403A1

    公开(公告)日：2006-03-09

    申请号：US10528343

    申请日：2003-09-26

    申请人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    发明人： Yoshiaki Isobe ,  Haruo Takaku ,  Haruhisa Ogita ,  Masanori Tobe ,  Ayumu Kurimoto ,  Tetsuhiro Ogino ,  Hitoshi Fujita

    IPC分类号： A61K31/52 ,  C07D473/12 ,  C07D473/14

    CPC分类号： A61K31/5377 ,  A61K31/522 ,  A61K31/55

    摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

    摘要翻译： 用作局部给药的药物，其作为抗过敏剂有效。 用于局部给药的药物含有由通式（1）表示的腺嘌呤化合物作为活性成分：